[Federal Register Volume 84, Number 161 (Tuesday, August 20, 2019)]
[Notices]
[Page 43139]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-17933]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0411]


Bristol-Myers Squibb Co. et al.; Withdrawal of Approval of 70 New 
Drug Applications and 97 Abbreviated New Drug Applications; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice 
that appeared in the Federal Register of June 8, 2011. The document 
announced the withdrawal of approval of 70 new drug applications (NDAs) 
and 97 abbreviated new drug applications from multiple applicants, 
effective July 8, 2011. The document contained the incorrect applicant 
information for NDA 018380. The correct applicant for NDA 018380 is 
Hospira, Inc. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Florine Purdie, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, Rm. 6248, Silver Spring, MD 20993-0002, 301-
796-3601.

SUPPLEMENTARY INFORMATION: In the Federal Register of Wednesday, June 
8, 2011 (76 FR 33310), appearing on page 33310 in FR Doc. 2011-14164, 
the following correction is made:
    On page 33311, in table 1, in the ``Applicant'' column for NDA 
018380, correct the entry ``Do.'' to read ``Hospira, Inc., 275 North 
Field Dr., Bldg. H2, Lake Forest, IL 60045-5046.''

    Dated: August 14, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-17933 Filed 8-19-19; 8:45 am]
 BILLING CODE 4164-01-P